← Back to Search
Breast Cancer Subtypes And The Risk Of Local And Regional Relapse.
K. D. Voduc, M. Cheang, S. Tyldesley, K. Gelmon, T. Nielsen, H. Kennecke
Published 2010 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
PURPOSE The risk of local and regional relapse associated with each breast cancer molecular subtype was determined in a large cohort of patients with breast cancer. Subtype assignment was accomplished using a validated six-marker immunohistochemical panel applied to tissue microarrays. PATIENTS AND METHODS Semiquantitative analysis of estrogen receptor (ER), progesterone receptor (PR), Ki-67, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and cytokeratin (CK) 5/6 was performed on tissue microarrays constructed from 2,985 patients with early invasive breast cancer. Patients were classified into the following categories: luminal A, luminal B, luminal-HER2, HER2 enriched, basal-like, or triple-negative phenotype-nonbasal. Multivariable Cox analysis was used to determine the risk of local or regional relapse associated the intrinsic subtypes, adjusting for standard clinicopathologic factors. RESULTS The intrinsic molecular subtype was successfully determined in 2,985 tumors. The median follow-up time was 12 years, and there have been a total of 325 local recurrences and 227 regional lymph node recurrences. Luminal A tumors (ER or PR positive, HER2 negative, Ki-67 < 1%) had the best prognosis and the lowest rate of local or regional relapse. For patients undergoing breast conservation, HER2-enriched and basal subtypes demonstrated an increased risk of regional recurrence, and this was statistically significant on multivariable analysis. After mastectomy, luminal B, luminal-HER2, HER2-enriched, and basal subtypes were all associated with an increased risk of local and regional relapse on multivariable analysis. CONCLUSION Luminal A tumors are associated with a low risk of local or regional recurrence. Molecular subtyping of breast tumors using a six-marker immunohistochemical panel can identify patients at increased risk of local and regional recurrence.
This paper references
Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1-ST2 breast cancer.
P. Truong (2002)
Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer.
S. Crabb (2008)
Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen
G. Martelli (2008)
Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression.
P. H. M. Elkhuizen (1999)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
M. Clarke (2005)
Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20
E Mamounas (2005)
Molecular markers for prognosis after isolated postmastectomy chest wall recurrence
Bruce G. Haffty (2004)
Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies.
M. Colleoni (2004)
Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival
L. Fulford (2006)
Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy.
P. Truong (2005)
Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.
J. Ragaz (1997)
Molecular portraits of human breast tumours
C. Perou (2000)
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
patients treated by conservative surgery alone plus adjuvant tamoxifen : Fifteen - year results of a prospective study
SJ Crabb (2008)
Predicting the risk of local recurrence in patients with breast cancer: an approach to a new computer-based predictive tool.
M. Sanghani (2007)
Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients.
R. Zellars (2000)
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
M. Overgaard (1997)
Gene expression profiling predicts clinical outcome of breast cancer
L. J. Veer (2002)
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
T. Nielsen (2004)
Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.
A. Ringberg (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
R. Dent (2007)
p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
M. D. de Roos (2007)
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
M. Kyndi (2008)
Anti-apoptotic phenotype is associated with decreased locoregional recurrence rate in breast cancer.
J. Jager (2000)
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
M. Cheang (2006)
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
P. Nguyen (2008)
Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers.
T. Hieken (2001)
Compliance with practice guidelines for node-negative breast cancer.
A. Olivotto (1997)
Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial
M. Overgaard (1999)
Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
C. Louvet (1998)
Molecular analysis of local relapse in high-risk breast cancer patients: can radiotherapy fractionation and time factors make a difference?
M. Koukourakis (2003)
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
B. Haffty (2006)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T. Sørlie (2003)
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
M. Cheang (2008)
Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
E. Millar (2009)
Predicting a local recurrence after breast-conserving therapy by gene expression profiling
D. Nuyten (2006)
Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study
Michelle K Nottage (2006)
Local therapy and survival in breast cancer.
B. Fisher (2007)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
S. Paik (2004)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
M. Cheang (2009)
Two Distinct Local Relapse Subtypes in Invasive Breast Cancer: Effect on their Prognostic Impact
P. Casalini (2008)
Statistical analysis of proliferative index data in clinical trials.
P. Grambsch (1994)
This paper is referenced by
Preoperative Measurement of Breast Cancer Overestimates Tumor Size Compared to Pathological Measurement
Y. Jiang (2014)
Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer
E. Y. Chae (2016)
Tumor Secretion of CCL22 Activates Intratumoral Treg Infiltration and Is Independent Prognostic Predictor of Breast Cancer
Y. Li (2013)
Perfusion studies in senology.
C. de Bazelaire (2013)
Prognosis following local recurrence after breast conserving treatment in young women with early breast cancer.
M. V. D. van der Sangen (2013)
Survival impact of primary site surgery on metastatic breast cancer patients at diagnosis.
H. Desille-Gbaguidi (2019)
Multilevel heterogeneous omics data integration with kernel fusion
H. Yang (2020)
Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up
Karama Asleh (2017)
Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study
A. Hennigs (2016)
Expression of p53 Breast Cancer in Kurdish Women in the West of Iran: a Reverse Correlation with Lymph Node Metastasis.
M. Payandeh (2016)
Polimorfismo genético do fator de transcrição FOXP3 em pacientes com câncer de mama
Caroline Yukari Motoori-Fernandes (2019)
Serum endocan level and its prognostic significance in breast cancer patients
O. Ates (2018)
Discrimination of tumor from normal tissues in a mouse model of breast cancer using CARS spectroscopy combined with PC‐DFA methodology
Xi S. Huang (2017)
Adjuvant Radiation Therapy After Preoperative Chemotherapy
M. Fayda (2016)
Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence
Roberta Piva (2017)
Targeting triple-negative sporadic and hereditary BRCA-related metastatic breast cancer
Sarah M. Barton (2011)
How could breast cancer molecular features contribute to locoregional treatment decision making?
P. G. Tsoutsou (2017)
Tumor-associated macrophages and microglia : double-edged sword in tumor evolvement and invasion
Tatjana Wallmann (2018)
Algorithms and applications of next-generation DNA sequencing : ChIP-Seq, database of human variations, and analysis of mammary ductal carcinomas
Anthony P. Fejes (2012)
Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015 he ACOSOG-Z 0011 and AMAROS Era A Dutch Population-based Study in t
Ingrid G. M. Poodt (2017)
Predicting non‐sentinel lymph node metastasis in Australian breast cancer patients: are the nomograms still useful in the post‐Z0011 era?
G. Tapia (2019)
Clinicopathological features and treatment strategy for triple-negative breast cancer
Y. Yamamoto (2010)
Triple-negative breast cancer.
W. Foulkes (2010)
The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer
Z. Gabos (2010)
Estrogen, Progesterone and Human epidermal growth factor receptor -2 in malignant breast lesions: A 5 year study in a tertiary care hospital of Karnataka
Sujoy Kumar De (2015)
Staging and Workup of Invasive Breast Cancer
V. Sacchini (2015)
Leveraging the clinical microsystem to offset the limitations of breast cancer screening in the united states
Frida Velcani (2019)
Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study
Y. Gong (2017)
Omission of Breast Radiotherapy in Low-risk Luminal A Breast Cancer: Impact on Health Care Costs.
K. Han (2016)
The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.
S. Lakis (2014)
CHD4‐mediated loss of E‐cadherin determines metastatic ability in triple‐negative breast cancer cells
Chi-Wen Luo (2018)
Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes
S. Park (2012)See more